



Symposium on

Breast Cancer: The Triple Negative Paradox

29 August 2018 (9.00 to 12.30)
Jónas Einarsson Auditorium, Oslo Cancer Cluster Innovation Park

Dear All,

This is to cordially invite you to the symposium on “Breast Cancer: The Triple Negative Paradox” @ 29th August 2018. Triple-negative breast cancer (sometimes abbreviated TNBC) refers to any breast cancer that does not express the genes for estrogen receptor (ER), progesterone receptor (PR) and Her2/neu. This makes it more difficult to treat since most hormone therapies target one of the three receptors, so triple-negative cancers often require combination therapies. TNBC can be more aggressive and difficult to treat due to the fact that it is more likely to spread and recur. The symposium will focus on drug discovery, biomarkers and treatment aspects of TNBC. Participants will gain a broad exposure to the fundamental mechanisms driving TNBC through presentations from three speakers discussing the recent advances in this cancer subtype. The Networking session at the end of the symposium will focus on Horizon 2020 funding opportunities for both academia and industry in the field of cancer and personalised medicine.

Speakers

Prof. Andrew Westwell, Cardiff University, United Kingdom
Prof. Emiel Janssen, Stavanger University Hospital, Norway
Dr. Claudia Bøen, Arctic Pharma AS, Norway
Dr. Gupta Udatha, Oslo Cancer Cluster

Registration

This event is FREE to attend and you can send your registration by filling the form at the event page.

This symposium is supported and arranged in co-operation with: